Short-term supplementation with Aronia melanocarpa extract improves platelet aggregation, clotting, and fibrinolysis in patients with metabolic syndrome

Sikora, Joanna; Broncel, Marlena; Markowicz, Magdalena; Chałubiński, Maciej; Wojdan, Katarzyna; Mikiciuk-Olasik, Elżbieta

doi:10.1007/s00394-011-0238-8

Cited by 64 publications

(67 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven studies used the product Aronox R (Agropharm Ltd, Poland), which contained 15 mg of anthocyanins in a 100-mg tablet at a daily dose of three tablets (300 mg) per day-giving a daily dose of 45 mg of anthocyanins . A later exploratory study in patients suffering from metabolic syndrome investigated a daily dose of 300 mg of chokeberry extract, giving a daily dose of 80 mg of the total polyphenols that included at least 60 mg of anthocyanins (Sikora et al, 2012): this confirmed that blood lipids significantly decreased over 2 months of treatment. Beneficial changes in coagulation indices (reduction in adenosine diphosphate-induced clot formation and inhibition of the amidolytic activities of both thrombin and plasmin) were also observed (Sikora et al, 2012;Sikora et al, 2014a).…”

Section: Discussionmentioning

confidence: 88%

“…A later exploratory study in patients suffering from metabolic syndrome investigated a daily dose of 300 mg of chokeberry extract, giving a daily dose of 80 mg of the total polyphenols that included at least 60 mg of anthocyanins (Sikora et al ., ): this confirmed that blood lipids significantly decreased over 2 months of treatment. Beneficial changes in coagulation indices (reduction in adenosine diphosphate‐induced clot formation and inhibition of the amidolytic activities of both thrombin and plasmin) were also observed (Sikora et al ., ; Sikora et al ., ). In accordance with this, an improvement of the rheological properties of erythrocytes was shown in hypercholesterolemic patients receiving 300‐mg Aronox R over 2 months (Duchnowicz et al ., ).…”

Section: Discussionmentioning

confidence: 97%

“…The doses used in such experimental studies were more than 30 times higher than those used in the clinical studies, where the daily doses contained a maximum of 60-mg anthocyanins Sikora et al, 2012). Further studies should investigate whether there is a dose-dependent effect and which dose gives the best results.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Quantification of Anthocyanins in Elderberry and Chokeberry Dietary Supplements

Vlachojannis

Zimmermann

Chrubasik‐Hausmann

2015

Phytotherapy Research

View full text Add to dashboard Cite

Elderberry and chokeberry food supplements may be 'functional food' in patients with metabolic syndrome or influenza but, for this, adequate amounts of co-active ingredients must be consumed in the daily dose. This study aimed to quantify the anthocyanin content in three elderberry and six chokeberry products to assess their usefulness as functional food. Analyses were carried out using an established HPLC procedure. The minimum anthocyanin doses for the treatment of metabolic syndrome disorders were estimated as 110 mg per day and 3.5 g per day for influenza. Three products were inappropriate for clinical use. The lowest liquid supplies were achieved with a proprietary elderberry concentrate (11 mL) and a proprietary chokeberry mother juice (100 mL). Clinical studies are now required to prove the effectiveness and adapt the doses according to the clinical symptoms.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Quantification of Anthocyanins in Elderberry and Chokeberry Dietary Supplements

Vlachojannis

Zimmermann

Chrubasik‐Hausmann

2015

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Serum triglycerides were also significantly decreased, as well as parameters of platelet aggregation and coagulation [45]. …”

Section: Chokeberrymentioning

confidence: 99%

Berry Fruit Consumption and Metabolic Syndrome

et al. 2016

View full text Add to dashboard Cite

Metabolic Syndrome is a cluster of risk factors which often includes central obesity, dyslipidemia, insulin resistance, glucose intolerance, hypertension, endothelial dysfunction, as well as a pro-inflammatory, pro-oxidant, and pro-thrombotic environment. This leads to a dramatically increased risk of developing type II diabetes mellitus and cardiovascular disease, which is the leading cause of death both in the United States and worldwide. Increasing evidence suggests that berry fruit consumption has a significant potential in the prevention and treatment of most risk factors associated with Metabolic Syndrome and its cardiovascular complications in the human population. This is likely due to the presence of polyphenols with known antioxidant and anti-inflammatory effects, such as anthocyanins and/or phenolic acids. The present review summarizes the findings of recent dietary interventions with berry fruits on human subjects with or at risk of Metabolic Syndrome. It also discusses the potential role of berries as part of a dietary strategy which could greatly reduce the need for pharmacotherapy, associated with potentially deleterious side effects and constituting a considerable financial burden.

show abstract

“…In another study, Sikora et al . () investigated the effects of A . melanocarpa extract supplementation on platelet aggregation, clot formation, and lysis in patients with metabolic syndrome.…”

Section: Antiplatelet Properties Of Medicinal Plants: Bioactive Constmentioning

confidence: 99%

Medicinal Plants with Antiplatelet Activity

Haouari

Rosado

2016

Phytother. Res.

View full text Add to dashboard Cite

Blood platelets play an essential role in the hemostasis and wound-healing processes. However, platelet hyperactivity is associated to the development and the complications of several cardiovascular diseases. In this sense, the search for potent and safer antiplatelet agents is of great interest. This article provides an overview of experimental studies performed on medicinal plants with antiplatelet activity available through literature with particular emphasis on the bioactive constituents, the parts used, and the various platelet signaling pathways modulated by medicinal plants. From this review, it was suggested that medicinal plants with antiplatelet activity mainly belong to the family of Asteraceae, Rutaceae, Fabaceae, Lamiaceae, Zygophyllaceae, Rhamnaceae, Liliaceae, and Zingiberaceae. The antiplatelet effect is attributed to the presence of bioactive compounds such as polyphenols, flavonoids, coumarins, terpenoids, and other substances which correct platelet abnormalities by interfering with different platelet signalization pathways including inhibition of the ADP pathway, suppression of TXA2 formation, reduction of intracellular Ca(2+) mobilization, and phosphoinositide breakdown, among others. The identification and/or structure modification of the plant constituents and the understanding of their action mechanisms will be helpful in the development of new antiplatelet agents based on medicinal plants which could contribute to the prevention of thromboembolic-related disorders by inhibiting platelet aggregation. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Short-term supplementation with Aronia melanocarpa extract improves platelet aggregation, clotting, and fibrinolysis in patients with metabolic syndrome

Cited by 64 publications

References 19 publications

Quantification of Anthocyanins in Elderberry and Chokeberry Dietary Supplements

Quantification of Anthocyanins in Elderberry and Chokeberry Dietary Supplements

Berry Fruit Consumption and Metabolic Syndrome

Medicinal Plants with Antiplatelet Activity

Contact Info

Product

Resources

About